BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 32599539)

  • 1. IL-7/αIL-7 mAb M25 immunocomplexes expand CD8
    Hrabos D; Hnizdilova T; Tomala J; Uhlik J; Kovar M
    Cytokine; 2020 Sep; 133():155174. PubMed ID: 32599539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
    Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
    Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy.
    Tomala J; Chmelova H; Mrkvan T; Rihova B; Kovar M
    J Immunol; 2009 Oct; 183(8):4904-12. PubMed ID: 19801515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
    Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA
    Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
    Desbois M; Le Vu P; Coutzac C; Marcheteau E; Béal C; Terme M; Gey A; Morisseau S; Teppaz G; Boselli L; Jacques Y; Béchard D; Tartour E; Cassard L; Chaput N
    J Immunol; 2016 Jul; 197(1):168-78. PubMed ID: 27217584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities.
    Coutzac C; Adam J; Soularue E; Collins M; Racine A; Mussini C; Boselli L; Kamsukom N; Mateus C; Charrier M; Cassard L; Planchard D; Ribrag V; Fizazi K; Loriot Y; Lepage P; Scoazec JY; Robert C; Carbonnel F; Chaput N
    J Crohns Colitis; 2017 Oct; 11(10):1238-1246. PubMed ID: 28967957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18.
    Ma Z; Li W; Yoshiya S; Xu Y; Hata M; El-Darawish Y; Markova T; Yamanishi K; Yamanishi H; Tahara H; Tanaka Y; Okamura H
    Clin Cancer Res; 2016 Jun; 22(12):2969-80. PubMed ID: 26755531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL2/Anti-IL2 Complex Combined with CTLA-4, But Not PD-1, Blockade Rescues Antitumor NK Cell Function by Regulatory T-cell Modulation.
    Caudana P; Núñez NG; De La Rochere P; Pinto A; Denizeau J; Alonso R; Niborski LL; Lantz O; Sedlik C; Piaggio E
    Cancer Immunol Res; 2019 Mar; 7(3):443-457. PubMed ID: 30651291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model.
    Yu P; Steel JC; Zhang M; Morris JC; Waldmann TA
    Clin Cancer Res; 2010 Dec; 16(24):6019-28. PubMed ID: 20924130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
    Redmond WL; Linch SN; Kasiewicz MJ
    Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B; Pommey S; Smyth MJ; Stagg J
    Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
    Kawano M; Itonaga I; Iwasaki T; Tsumura H
    Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
    Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
    Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
    Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
    Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-Mediated Phosphatidylserine Blockade Enhances the Antitumor Responses to CTLA-4 and PD-1 Antibodies in Melanoma.
    Freimark BD; Gong J; Ye D; Gray MJ; Nguyen V; Yin S; Hatch MM; Hughes CC; Schroit AJ; Hutchins JT; Brekken RA; Huang X
    Cancer Immunol Res; 2016 Jun; 4(6):531-40. PubMed ID: 27045021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8
    Hutmacher C; Gonzalo Núñez N; Liuzzi AR; Becher B; Neri D
    Cancer Immunol Res; 2019 Apr; 7(4):572-583. PubMed ID: 30782667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4
    Beavis PA; Henderson MA; Giuffrida L; Davenport AJ; Petley EV; House IG; Lai J; Sek K; Milenkovski N; John LB; Mardiana S; Slaney CY; Trapani JA; Loi S; Kershaw MH; Haynes NM; Darcy PK
    Cancer Immunol Res; 2018 Sep; 6(9):1069-1081. PubMed ID: 30018045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL36 Cooperates With Anti-CTLA-4 mAbs to Facilitate Antitumor Immune Responses.
    Qu Q; Zhai Z; Xu J; Li S; Chen C; Lu B
    Front Immunol; 2020; 11():634. PubMed ID: 32351508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells.
    Takaku S; Terabe M; Ambrosino E; Peng J; Lonning S; McPherson JM; Berzofsky JA
    Int J Cancer; 2010 Apr; 126(7):1666-74. PubMed ID: 19830696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
    Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
    Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.